INDICES OF SERUM ANDROGENS IN NORMAL PUBERTY: CORRELATIONS OF TWO INDICES WITH CHRONOLOGICAL AGE, BONE AGE AND PUBERTAL DEVELOPMENT IN BOYS AND GIRLS

1981 ◽  
Vol 15 (2) ◽  
pp. 183-192 ◽  
Author(s):  
J. L. PENFOLD ◽  
T. C. SMEATON ◽  
J. M. GILLILAND ◽  
T. J. C. BOULTON ◽  
M. J. THOMSETT ◽  
...  
Keyword(s):  
Pubertal Development ◽  
Bone Age ◽  
Chronological Age ◽  
Two Indices ◽  
Serum Androgens

scholarly journals Growth and Pubertal Development in Elite Female Rhythmic Gymnasts

1999 ◽  
Vol 84 (12) ◽  
pp. 4525-4530 ◽  
Author(s):  
N. Georgopoulos ◽  
K. Markou ◽  
A. Theodoropoulou ◽  
P. Paraskevopoulou ◽  
L. Varaki ◽  
...  
Keyword(s):  
Body Fat ◽  
Adult Height ◽  
Pubertal Development ◽  
Optimal Growth ◽  
Bone Age ◽  
Skeletal Maturation ◽  
Chronological Age ◽  
Average Height ◽  
Limited Information ◽  
Rhythmic Gymnasts

Optimal growth depends upon both environmental and genetic factors. Among environmental factors that could alter growth and sexual maturation are stress and intensive physical training. The influence of these factors has been documented in a variety of sports, but there is limited information on rhythmic gymnasts, who have entirely different training and performance requirements. The study was conducted during the 13th European Championships in Patras, Greece, and included 255 female rhythmic gymnasts, aged 11–23 yr. The study included measurement of height and weight, assessment of breast and pubic hair development, estimation of body fat and skeletal maturation, and registration of menarcheal age and parental height. Gymnasts were taller than average height for age, with mean height above and mean weight below the 50th percentile. Actual height sd score was positively correlated to weight sd score (P < 0.001), number of competitions (P = 0.01), and body mass index (BMI; P < 0.001). Predicted adult height sd score was positively correlated to weight sd score (P < 0.001) and negatively to body fat (P = 0.004). There was a delay in skeletal maturation of 1.3 yr (P < 0.001). Pubertal development was following bone age rather than chronological age. The mean age of menarche was significantly delayed from that of their mothers and sisters (P = 0.008 and P = 0.05, respectively), was positively correlated to the intensity of training and to the difference between chronological age and bone age (P < 0.001 and P = 0.002, respectively), and was negatively correlated to body fat (P < 0.001). In the elite female rhythmic gymnasts, psychological and somatic efforts have profound effects on growth and sexual development. Despite these aberrations, adult height is not expected to be affected.

Retrospective evaluation of pubertal development and linear growth of girls with Turner Syndrome treated with oral and transdermal estrogen

2015 ◽  
Vol 28 (11-12) ◽  
Author(s):  
Esra D.P. Çakır ◽  
Halil Sağlam ◽  
Erdal Eren ◽  
Taner Özgür ◽  
Ömer F. Tarım
Keyword(s):  
Turner Syndrome ◽  
Linear Growth ◽  
Pubertal Development ◽  
Bone Age ◽  
Treated Group ◽  
Breast Development ◽  
Chronological Age ◽  
Retrospective Evaluation ◽  
Left Hand ◽  
Transdermal Estrogen

AbstractThe objective of the study was to evaluate the pubertal development and linear growth of Turner Syndrome (TS) girls regularly monitored in our department.The data of 13 patients with TS were evaluated retrospectively. Left hand radiograms were evaluated by three different pediatric endocrinologists to determine bone ages.Six (46.2%) of the TS girls were treated with oral estrogens, while 7 (53.8%) were treated with transdermal estrogen. The ratios of chronological age (CA) difference to bone age (BA) difference (ΔCA/ΔBA) in two groups of patients treated with estrogen were compared at the time of the last control. The ΔCA/ΔBA ratio in the transdermal estrogen-treated group was significantly higher (p=0.005). These results suggest slower BA progression in the TS girls treated with transdermal estrogen.BA advancement is less significant with transdermal estrogen, which is associated with adequate breast development.

scholarly journals Selective effects of biological and chronological age on the development of cognitive abilities in adolescence

2021 ◽  
Author(s):  
Ilona Kovacs ◽  
Kristof Kovacs ◽  
Patricia Gervan ◽  
Katinka Utczas ◽  
Gyongyi Olah ◽  
...  
Keyword(s):  
Cognitive Abilities ◽  
Skeletal Maturity ◽  
Pubertal Timing ◽  
Working Memory Capacity ◽  
Bone Age ◽  
Gonadal Hormones ◽  
Individual Variability ◽  
Biological Age ◽  
Chronological Age ◽  
Biological Maturity

Adolescent development is not only shaped by the mere passing of time and accumulating experience, it also depends on pubertal timing and the cascade of maturational processes orchestrated by gonadal hormones. Although individual variability in puberty onset confounds adolescent studies, it has not been efficiently controlled for. Here we introduce ultrasonic bone age assessment to estimate biological maturity and disentangle the independent effects of chronological and biological age on adolescent cognitive abilities. Comparing cognitive performance of participants with different skeletal maturity we uncover the striking impact of biological age on both IQ and specific abilities. We find that biological age has a selective effect on abilities: more mature individuals within the same age group have higher working memory capacity and processing speed, while those with higher chronological age have better verbal abilities, independently of their maturity. Based on our findings, bone age is a promising biomarker for adolescent research.

scholarly journals Growth for 12 Years After Resection of Virilizing Adrenocortical Adenoma: Observation of Linear Growth, Bone Age and Pubertal Development

1994 ◽  
Vol 3 (Supple4) ◽  
pp. 163-167
Author(s):  
Yuko Nakayama ◽  
Osamu Arisaka ◽  
Sachi Fujiwara ◽  
Atsuto Hosaka ◽  
Naoto Shimura ◽  
...  
Keyword(s):  
Linear Growth ◽  
Pubertal Development ◽  
Bone Age ◽  
Adrenocortical Adenoma

LONG-TERM TREATMENT OF DWARFISM WITH ANDROGENS AND THYROID HORMONE

1959 ◽  
Vol XXXII (IV) ◽  
pp. 563-574 ◽  
Author(s):  
H. Hortling ◽  
K. Wahlfors
Keyword(s):  
Thyroid Hormone ◽  
Bone Age ◽  
Term Treatment ◽  
Point Of View ◽  
Chronological Age ◽  
Long Term Treatment ◽  
Thyroid Medication ◽  
Height Increase ◽  
Delayed Closure

ABSTRACT In 7 cases of dwarfism with markedly delayed closure of the epiphyses, methyltestosterone was administered sublingually in doses of 5–10 (25) mg daily in combination with thyroid hormone in doses of 25–120 mg daily for 2–7 years. At the institution of treatment the patients were 9, 11, 15, 15, 16, 17 and 20 years old and were 95, 125, 119, 124, 120, 135 and 125 cm in height respectively. The bone age was in all cases checked against Greulich & Pyle's radiographic tables (1950). During the first two years of therapy, 5 patients exhibited a more rapid increase of the bone age than was to be expected considering their chronological age. In 5 cases where the therapy was continued over a longer period of time, such a tendency was not demonstrable later, although the dosage of methyltestosterone was often somewhat increased. On the contrary, a retardation of the bone age development occurred, as compared with the chronological age. In none of the present cases have the epiphyses become closed, notwithstanding a considerable height increase in all cases, i. e. 15–29 cm depending on the length of the period of treatment, and the relatively advanced age of the patients at the time of writing when they are still under androgen therapy with or without thyroid medication. Provided that the bone age is continuously checked, it appears that methyltestosterone in small doses can safely be used in the treatment of dwarfism with delayed closure of the epiphyses. This trea[ill]ment proved to be of great importance from the point of view of the choice of a vocation as well as for the future life of the patients.

scholarly journals Adult Height in Girls with Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogues and Growth Hormone

1999 ◽  
Vol 84 (2) ◽  
pp. 449-452 ◽  
Author(s):  
Anna Maria Pasquino ◽  
Ida Pucarelli ◽  
Maria Segni ◽  
Marco Matrunola ◽  
Fabio Cerrone
Keyword(s):  
Precocious Puberty ◽  
Adult Height ◽  
Final Height ◽  
Pubertal Development ◽  
Central Precocious Puberty ◽  
Chronological Age ◽  
Control Group ◽  
Bone Maturation ◽  
Gnrh Analogues ◽  
Age Progression

GnRH analogues (GnRHa) represent the treatment of choice in central precocious puberty (CPP), because arresting pubertal development and reducing either growth velocity (GV) or bone maturation (BA) should improve adult height. However, in some patients, GV decrease is so remarkable that it impairs predicted adult height (PAH); and therefore, the addition of GH is suggested. Out of twenty subjects with idiopathic CPP (treated with GnRHa depot-triptorelin, at a dose of 100 μg/kg im every 21 days, for at least 2–3 yr), whose GV fall below the 25th percentile for chronological age, 10 received, in addition to GnRHa, GH at a dose of 0.3 mg/kg·week sc, 6 days weekly, for 2–4 yr; and 10 matched for BA, chronological age, and duration of GnRHa treatment, who showed the same growth pattern but refused GH treatment, served to evaluate the efficacy of GH addition. No patient showed classical GH deficiency. Both groups discontinued treatment at a comparable BA (mean ± sem): 13.2 ± 0.2 in GnRHa plus GH vs. 13.0 ± 0.1 yr in the control group. At the conclusion of the study, all the patients had achieved adult height. Adult height was considered to be attained when the growth during the preceding year was less than 1 cm, with a BA of over 15 yr. Patients of the group treated with GH plus GnRHa showed an adult height significantly higher (P < 0.001) than pretreatment PAH (160.6 ± 1.3 vs. 152.7 ± 1.7 cm). Target height (TH) was significantly exceeded. The group treated with GnRH alone reached an adult height not significantly higher than pretreatment PAH (157.1 ± 2.5 vs. 155.5 ± 1.9 cm). TH was just reached but not significantly exceeded. The gain in centimeters obtained, calculated between pretreatment PAH and final height, was 7.9 ± 1.1 cm in patients treated with GH combined with GnRHa; whereas in patients treated with GnRHa alone, the gain was just 1.6 ± 1.2 cm (P = 0.001). Furthermore, no side effects have been observed either on bone age progression or ovarian cyst appearance and the gynecological follow-up in the GH-treated patients (in comparison with those treated with GnRHa alone). In conclusion, a gain of 7.9 cm in adult height represents a significant improvement, which justifies the addition of GH for 2–3 yr during the conventional treatment with GnRHa, especially in patients with CPP, and a decrease in GV so marked as to impair PAH, not allowing it to reach even the third centile.

scholarly journals Experience with the use of domestic somatotropin Rastan for the treatment of children with Turner syndrome

2010 ◽  
Vol 56 (3) ◽  
pp. 11-15
Author(s):  
I I Dedov ◽  
N N Volevodz ◽  
O A Malievskiĭ ◽  
V A Peterkova
Keyword(s):  
Growth Rate ◽  
Turner Syndrome ◽  
Bone Age ◽  
Therapeutic Modality ◽  
Chronological Age ◽  
Recombinant Growth Hormone ◽  
Subcutaneous Injections ◽  
The Mean ◽  
Second Year ◽  
Recombinant Somatotropin

The objective of the present study was to evaluate the efficiency and safety of the treatment of girls presenting with Turner syndrome by recombinant growth hormone Rastan (Farmstandart-UfaVITA). A total 29 girls in this condition were available for observation. Their chronological age at the time of diagnosis averaged 7.9±1.2 years at the time of diagnosis and 9.8±1.6 at the onset of therapy; the bone age was 7.5±1.1 years. Duration of the treatment was 24 months. Recombinant somatotropin was used in the form of lyophilisate (1.33 mg) to prepare a solution for subcutaneous injections at a dose of 0.05 mg/kg of body weight. The solution was administered daily at evening hours. The mean growth rate of the patients with Turner syndrome was estimated at 4.2±0.6 cm/year prior to Rastan therapy, 8.7±0.6 cm/year during the first 12 months of the treatment, and 6.1±1.2 cm/yr in the second year. Overall, the height of the girls increased by 0.84 SD within the two years. No adverse effects of therapy were documented. It is concluded that the use of recombinant somatotropin Rastan is an efficacious and safe therapeutic modality for the acceleration of growth in girls with Turner syndrome.

Sign in / Sign up

Export Citation Format

Share Document